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Current clinical anti-CD40 biologic agents include both antagonist molecules for the treatment of autoimmune
diseases and agonist molecules for immuno-oncology, yet the relationship between CD40 epitope and these
opposing biological outcomes is not well defined. This report describes the identification of potent antagonist
domain antibodies (dAbs) that bind to a novel human CD40-specific epitope that is divergent in the CD40 of
nonhuman primates. A similarly selected anti-cynomolgus CD40 dAb recognizing the homologous epitope is
also a potent antagonist. Mutagenesis, biochemical, and X-ray crystallography studies demonstrate that the
epitope is distinct from that of CD40 agonists. Both the human-specific and cynomolgus-specific molecules
remain pure antagonists even when formatted as bivalent Fc-fusion proteins, making this an attractive
therapeutic format for targeting hCD40 in autoimmune indications.
© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Molecules belonging to the TNF/TNF-receptor
superfamily play important and obligatory roles in
various facets of the innate and adaptive immune
responses. The CD40/CD40L (CD154) pathway is an
example of one receptor/ligand pair that exerts
pleiotropic effects on various cellular subsets, partic-
ularly in the context of infection, inflammation,
autoimmunity and transplant rejection, and tumor
immunity [1,2]. CD40 is widely expressed and
delivers activating intracellular signals that are
analogous to the TNFR. Activated antigen-presenting
cells (APCs) express high levels of CD40, while lower
levels are noted among other cell types including
epithelial cells, endothelial cells, and platelets. On the
other hand, CD40L has little to no signaling capacityuthors. Published by Elsevier Ltd. This
rg/licenses/by-nc-nd/4.0/).and is selectively expressed by activated T cells and
platelets [3]. The CD40/CD40L pathway amplifies the
qualitative and quantitative nature of T–APC interac-
tions as highlighted by several key biological observa-
tions including (1) up-regulation of co-stimulatory CD80
andCD86molecules on theAPCs; (2) increased levels
of class I and II MHC molecules; (3) production of
pro-inflammatory cytokines including IL-12, IL-23, TNF,
and IL-6; (4) CD4 T cell help that aids the differentiation
of naive CD8 T cells into cytolytic effector CD8 T cells;
and, (5) in the case of B cells, CD40 signals are
absolutely critical for antibody class switching and
affinitymaturation [1]. The importanceof the last point is
highlighted by human subjects suffering from the
immuno-deficient condition termed the “hyper IgM
syndrome” wherein mutations in either CD40 or
CD40L result in lack of isotype switching from the
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2861Epitope-Specific Antagonism of CD40naive IgM phenotype [4–6]. These patients are
susceptible to opportunistic infections particularly
focused on upper and lower respiratory tract, resulting
in pneumonia and neutropenia [7,8].
The wide impact of the CD40/CD40L axis on a
variety of immune cells makes this pathway an
attractive target for modulation of inflammatory
immune responses. Indeed, knockout animals of
CD40 or CD40L exhibit impaired T and B cell
responses, and a blockade of CD40 or CD40L
results in protection from autoimmunity in various
pre-clinical models including arthritis, experimental
autoimmune encephalomyelitis, type 1 diabetes,
colitis, and lupus, and also results in prevention of
transplant rejection [9–16]. On the other hand,
activation of CD40 by cross-linking with monoclonal
antibodies (mAbs) results in effective anti-tumor
immune responses [17]. These opposing biological
outcomes suggest the presence of distinct sites on
the CD40 molecule that can modulate effects
ranging from complete antagonist activity to potent
agonism by delivering activating signals. To this end,
the current, clinical landscape of biologic agents
targeting CD40 is represented by anti-CD40 antag-
onist molecules that are being pursued for autoim-
munity and prevention of transplant rejection and by
ant i -CD40 agonis t molecules for use in
immuno-oncology [17–20].
In this report, we described the generation of small
antibody fragment molecules termed domain antibod-
ies (dAbs) [21] that target the human CD40 (hCD40)
molecule and characterize the relationship between
specific binding epitopes and biological activity. In
particular, we identify hCD40-specific antagonist dAbs
that possess no cross-reactivity toward nonhuman
primates (NHP), and we target a unique hCD40-
specific epitope within the C-terminal region that is
distinct from the binding sites of previously reported
agonist mAbs. The molecular details of the CD40
interactions were revealed through determination of
X-ray crystal structures of hCD40 in complexwith either
an antagonist dAb or a noncompeting Fab fragment
from the clinical candidate mAb Chi220. To betterPCR primers were as follows:
Exon Forward Primer
1 TGTTCTGGGGAAACTCCTGCGCGGTGAATTGCTGGG
2 CTGTTTTGACTTGCACTTCAGTTTGCAGCCTCTGTCC
TGGATG
3 GGCCTGATCATTGTGTGGTTAGTGTCTGACTCATGGAG
TTGG
4 GGGAGTGAGGCTCAGAGCATGGCCCAGCAGG
5 CACTGGCTGCCTTGTGAGCCGGACAGGTGG
6 CAGTGAACCTGGATTTGTTGATTGTTGACTGACTCA
CTCTAGAG
7,8 GTCACAGCAGGTTGAGGGTAGGGAGAAACTGCAGG
9 CCAGGGAGGGGCTCCTCAGAGGCACAGCTGunderstand the relationship between the unique
binding site and biological activity, and to ultimately
enable in vivo experiments inNHPs,wealso generated
a surrogate dAb molecule that binds to cynomolgus
CD40 (cyCD40) at an analogous site as the
human-specific dAb binding site. The potency
of anti-CD40 dAbs and pure antagonist activity was
confirmed by extensive profiling in in vitro assays
including primary B cell proliferation, T–B cell mixed
lymphocyte reaction assays, and activation of primary
dendritic cells (DCs). Taken together, these studies
provide novel insight into the different targetable
domains of hCD40 and their use in designing protein
therapeutics for treatment of autoimmune disease or
immuno-oncology.Materials and Methods
Methods
Cloning, expression and purification of CD40 proteins
Thesequences for human, cynomolgus, and rhesusCD40
are from accession numbers AAO43990, XP_005569275.1,
and NP_00125279.1, respectively. The sequence of
chimpanzee CD40 had not been previously been
reported at the time of this work, so it was obtained by
sequencing the individual CD40 exons from chimpan-
zee's genomic DNA. Genomic DNA used for PCR with
subsequent sequencing was isolated from chimpanzee's
PBMCs according to Qiagen's “Dneasy Blood and Tissue
Kit”. Primers for the PCR amplification of each exon
were designed using the hCD40 genomic sequence as a
reference. PCR was performed using standard Taq
Polymerase (Invitrogen) with 40 cycles (1′ 56 °C, 1′
72 °C, and 30″ 95 °C with a 10′ extension after the last
cycle at 72 °C) in 10% DMSO followed by a cleanup using
ExoSAP-IT (USB, Affymetrix) according to manufacturer's
protocol. After sequencing, results were analyzed using
Sequencher and compared to the human reference
sequence to compile chimpanzee's CD40 full-length coding
sequence. It has since been deposited by others as
XP_009435602.1, which is identical to the sequence we
obtained.Reverse Primer
CCACAAAAATCAGCCAGGAAGGCCTCTTCCCCGAAG
GTCGTTTCAGATTTGAGTTTACAGTTAACATATGGGGTCT
GCGTCTG
GCAGACCCTGGCTACATAAAATTAGAATGGCTGCA
TTGTCGGG
CCAGCCCCTCACCTTGGGCCCTAAGCTCCTCTG
CAGGGACAGGACAGGTGGCTGGAGAGAATGGAGG
CCAGTGTTCCTGTGTGCCTCATCTCCCCCTTCAG
GCCCCATAGGCAACCGTGAGGCCATCTTCCCAG
GCAGCACCAGGCTCTCTGGCCAACTGCCTGTTTG
Internal primers specific for the desired PCR products were used as follows:
Exon Forward Reverse
1 GATAGGTGGACCGCGATTGG CCTTCTCATTCCCCACTCCC
2 CTGAAGAAGTTGCAACGGAGA AAAGGGGGACTCCATGATGG
3 ACTCATGGAGTTGGCCAGAG ATCAGCCCGGTTCCCAAGCG
4 GGGGGTTCCCATCCTTCCTG TCTGTCCCCCTCCAAAACTG
5 GTCCACTGTGATGGTTAATG CCATGCCACTCTTAGAGCAGG
6 AGTTGGAAATCTTATGCTTGG TCAGTTCCCACCTTCCTAGG
7,8 CTGCAGGTGAGGGGTGCATG CTTCCCAGTTTGTCAAAACTC
9 CAGCTGCCCCTGCTGCTGGG CCACGTGGCCACACTCCTGG
2862 Epitope-Specific Antagonism of CD40All mutants of human and cynomolgus CD40 entry
clone constructs were generated by PCR reactions
using wild-type entry clones as template. The genes
for the coding regions of dAb-Fc were synthesized
from GeneArt in their pENTR221 or pENTR2B entry
clone vectors. Genes of interest were introduced into
pTT22gate, pYD-gate, or pUCOE-gate vectors using
LR recombination. Proteins were produced in Dur-
ocher or UCOE expression systems. For Durocher
expression, HEK293-6E cells were transfected using a
DNA:PEI (Polyethylenimine) ratio of 1:2 in F17
medium (Invitrogen cat # A13835-01) containing
4 mM L-glutamine (Invitrogen cat# 25030-081) and
0.1% pluronic F68 (Invitrogen cat # 24040-032). The
day 5 conditioned medium was harvested for purifica-
tion. For UCOE expression, CHO-S cells were used to
generate a stable pool using DMRIE-C as transfection
reagent. The production media contained a 1:1 mixture
of CD CHO medium (Sigma cat # C0363) and CHO
medium (Invitrogen cat # 10743-029 with 1x TH from
(Invitrogen cat# 11067-030) and 8 mM final concen-
t rat ion of L-g lutamine from (Inv i t rogen cat#
25030-081). The day 7 conditioned medium was
harvested for purification.
Human or cynomolgus CD40 (1–193) extracellular
domains fused to a thrombin cleavable human IgG1 Fc
were purified from conditioned media using protein A
Sepharose fast flow (GE Healthcare cat # 17-1279-04)
and superdex-200 (GE Healthcare cat # 28-9893-36)
columns. The Fc was removed by cleavage with 1 unit/mg
biotinylated thrombin (Novagen 69672-3) for 2 h. Biotinyl-
ated thrombin was removed using streptavidin-agarose
(Novagen 69203-3), and the cleaved CD40 extracellular
domain was collected in the flow fraction of a protein A
column. The CD40 monomer was biotinylated with
sulfo-N-hydroxysuccinimide (NHS)-LC-LC-biotin (Pierce
cat# 21338) at a final incorporation of about 1.6–2.0 mol/
mol.
The hCD40 monomer used in structural studies was
deglycosylated using PNGase F (New England Biolabs
cat # P0704), followed by purification using Concanavalin
A Sepharose 4B resin (GE Healthcare cat # 17-0440-01)
and size exclusion chromatography (SEC) on a HiLoad
26/60 Superdex 75 prep grade column (GEHealthcare cat
# 17-1070-01). The deglycosylated hCD40 monomer was
complexed with either 3h-56-5 or Chi220-Fab in a molar
ratio of 1:2 and the complex purified on a Superdex-75
column.Phage selection and affinity maturation of domain
antibodies
Selections were performed using large synthetic dAb
repertoires [22] based on fully human scaffolds encoded
either by germline к light chain genes O12/O2/DPK9 and
Jк1 or heavy chain genes V3-23/DP47 and JH4b, with the
side chain diversity incorporated at positions in the
antigen-binding site. Phage particles were prepared and
purified as described [23] and then used in selections
against recombinant biotinylated monomeric human or
cynomolgus monkey CD40 fragment in solution. Three to
four rounds of selection were performed using 100 nM of
antigen in the first round, 100 or 10 nM of antigen in the
second, 10 or 1 nM in the third, and 1 nM in the fourth. The
phage/antigen mixture was incubated for 1 h, and antigen/
phage complexes were captured using streptavidin- or
NeutrAvidin-coated magnetic beads (alternating capture
reagent between rounds). The beads were washed with
PBS containing 0.1% (vol/vol) Tween 20 (PBST) and then
PBS. Bound phage were eluted in 0.5 ml of 100 μg/ml
trypsin in PBS for 10 min and then used to infect 2 ml of
log-phase Escherichia coli TG1 cells at 37 °C for 30 min.
Serial dilutions (for phage titer) and library plating were
performed on LB-Tet agar plates. For the next selection
round, cells were scraped from the plates and used to
inoculate 50 ml of 2xTY Tet at 37 °C for phage
amplification.
For affinity maturation by random mutagenesis, the
GeneMorph PCRmutagenesis kit II (Agilent Technologies)
was used to generate a library with an average mutation
rate of two to five amino acids per dAb. For targeted CDR
mutagenesis, several sub-libraries were generated using
oligonucleotides encoding the overlapping sets of three
randomized amino acid residues within the CDRs of the
dAb. The stringency of selections during affinity maturation
was increased by decreasing the concentration of the
biotinylated monomeric CD40 antigen down to 100 pM in
the third round and introducing competition with a
1000-fold excess of non-biotinylated CD40 Fc to isolate
variants with slow off-rates.Small-scale expression and screening of soluble dAbs
The genes encoding selected dAbs were cloned as
polyclonal selection outputs into a pUC-based,
ampicillin-resistant vector (containing a C-terminal myc
epitope tag where required for detection purposes). After
2863Epitope-Specific Antagonism of CD40transformation of E. coli and picking of individual colonies,
small-scale dAb expression was performed in 96-well
plates using Overnight Express lactose-based induction
system (Novagen) at 37 °C for 24 h. After centrifugation,
the supernatants were tested for binding to CD40 by
ELISA (naïve dAbs) or surface plasmon resonance (naïve
and affinity-matured variants).
For ELISA assays, a MaxiSorp 96-well immunoplate
(Nunc, USA) was coated with 1 μg/ml NeutrAvidin in 0.2 M
carbonate–bicarbonate buffer (pH 9.4). The plate was
then blocked with PBS containing 1% (vol/vol) Tween 20
(PBST). The plate was then washed and incubated with
0.7 μg/ml biotinylated CD40 in 0.1% PBST. The clarified
dAb-containing culture supernatant was added to the
ELISA plate with an equal volume of 0.1% PBST. After
incubation and washing, bound dAb was detected using a
two-step process. First, the plate was incubated with a
1:2000 dilution in 0.1% PBST of 9E10 (anti-myc monoclo-
nal antibody, Sigma-Aldrich, UK) and then washed. The
plate was then incubated with a 1:2000 dilution in 0.1%
PBST of anti-mouse Fc-HRP (Sigma-Aldrich, UK). The
plates were washed and the ELISA was developed using
3,3′,5,5′-tetramethylbenzidine. The colorimetric reaction
was stopped by the addition 1 M HCl and the ELISA plate
read at 450 nm.
Identification of dAbs that bind CD40 with improved
off-rates was performed using a Biacore3000 instrument.
1000 resonance units (RU) of biotinylated monomeric
CD40 fragment were immobilized on an SA Biacore chip
(GE Healthcare), and binding curves were generated by
flowing dAb supernatants diluted threefold in HBS–EP
buffer [0.01 M Hepes (pH 7.4) with 0.15 M NaCl, 3 mM
EDTA, and 0.005% vol/vol Surfactant P20, GE
Healthcare].Large-scale dAb expression
For larger scale expression, 500 ml inductions were
performed at 30 °C for 72 h. After cell pelleting by
centrifugation, the supernatants were incubated overnight
at 4 °C with either Streamline protein L or Streamline
protein A beads (GE Healthcare) for Vκ and VH dAbs,
respectively. The beads were then packed into drip
columns, washed with 10 column volumes of PBS, and
bound dAbs were eluted in 0.1 M glycine–HCl (pH 2.0).
After neutralization with 1 M Tris–HCl (pH 8.0), the protein
samples were dialyzed in PBS and concentrated on
Vivaspin 5-kDa concentrators (Vivascience). Endotoxin
levels were reduced to a maximum of 10 EU/mg using ion
exchange. Protein purity was estimated by visual analysis
after SDS-PAGE on 12% acrylamide Tris–glycine gel
(Invitrogen). Protein concentrations were measured at
280 nm using extinction coefficients calculated from the
amino acid compositions. Purified dAbs were character-
ized by numerous biophysical techniques including ana-
lytical SEC or SEC-MALS (multi-angle laser light
scattering), dynamic light scattering, and differential
scanning calorimetry, and those with favorable properties
were used in subsequent studies.Production of other protein reagents
CD40L was fused to a His-tagged trimerizing isoleucine
zipper (IZ) domain at the N terminus [24]. The genesencoding trimeric IZ human-CD40L (IZ-hCD40L) (108–
261) and IZ-mouse CD40L (107–260) were cloned into
Gateway entry vector pENTR2B, and CHO expression
constructs were generated by Gateway LR into BMS CHO
destination vector. The resulting IZ-hCD40L (108–261)
and IZ-mouse CD40L (107–260) proteins were expressed
in CHO cells. The clarified supernatants were buffer
exchanged into 25 mM sodium phosphate, 0.5 M NaCl,
10 mM imidazole, and 5% (vol/vol) glycerol (pH 7.3). The
His-IZ-CD40L were captured on a column of Ni-NTA
Superflow (Qiagen, cat# 30,450), washed with 25 mM
sodium phosphate, 0.5 M NaCl, 30 mM imidazole, and 5%
(vol/vol) glycerol (pH 7.3), and eluted using a gradient of
30–300 mM imidazole in the same buffer. Peak fractions
were pooled and 1 M ammonium sulfate was added. The
IZ-CD40L was run on a phenyl Sepharose column (GE
Healthcare cat# 17-1082-01). The column was washed
with 25 mM sodium phosphate, 1 M ammonium sulfate,
and 1 mM EDTA (pH 7.3) and eluted using a gradient from
1 to 0.5 M ammonium sulfate. The purest fractions were
pooled and run on a superdex-200 column in 25 mM
sodium phosphate, 0.5 M NaCl, and 10% (vol/vol) glycerol
(pH 7.0).
His-IZ-CD40L was biotinylated with a fivefold molar
excess of Sulfo-NHS-LC-LC-biotin in 25 mM sodium
phosphate and 0.5 M NaCl (pH 7.3) on ice for 2 h. The
reaction was quenched with 0.2 M Tris–HCl (pH 7.5)
for 30 min. The unreacted reagent and reaction bypro-
ducts were removed on a Sephadex-G25 column. The
final incorporation using the HABA assay (Pierce cat#
28,010) was determined to be 1.7 mol biotin/mol IZ-CD40L
trimer.
Production of Chi220 and G28-5 monoclonal antibodies
have been previously described [25,26]. To generate Fab
fragments, we first converted Chi220 and G28-5 antibod-
ies to a (Fab)2 by incubation with 1% pepsin (Sigma cat#
P6887) in 50 mM sodium citrate (pH 3.5) for 5 h at room
temperature. The reaction was quenched by adding Tris to
a final pH of 8. The (Fab)2 was collected in the flow fraction
of a protein A column and purified on a superdex-200
column. The (Fab)2 was converted to a Fab using mild
reduction with 10 mM cysteine in PBS for 6 h at room
temperature. The reaction was quenched and the reduced
cysteines were alkylated with 12 mM iodoacetamide
(Sigma I1149) for 30 min. The Fab fragments were purified
on a Superdex-200 column.Molecular modeling
In order to generate a homology model for CD40, a
member of the TNF receptor superfamily, we aligned the
sequence of CD40 to a structure-based alignment for six
TNF receptor superfamily members. The homology model
was created using the Build-Model-By-Homology protocol
provided in ICM (Molsoft, LLC). This is a completely
automated method that inherits the backbone from the
aligned (but not necessarily identical) parts of the
templates and then the extracted side chain conformations
for residues identical to the template were incorporated
into the model. Loops were inserted based upon confor-
mational database searches with matching loop ends.
Conformations for the nonidentical amino acid side chains
were assigned using the most likely rotamer, followed by
optimization using a torsional scan that relies upon
2864 Epitope-Specific Antagonism of CD40simultaneous global optimization of the energy for all
nonidentical residues using ICM biased probability Monte
Carlo optimization, followed by minimization. The six
templates used in the structure-based alignment are:
(PDB codes) 1JMA = Herpes simplex virus glycoprotein
D bound to the human receptor HveA; 2AW2 = BTLA–
HVEM complex; 2UWI = CrmE, a virus-encoded tumor
necrosis factor receptor; 2HEV = OX40–OX40L complex;
1NCF = tumor necrosis factor receptor; and 1TNR = TNF
beta complex. The structural model for the complex of
CD40L trimer and Chi220-Fab was generated based upon
superposition of one CD40L domain from the Chi220-
Fab:CD40L complex structure with a CD40L domain from
the CD40:CD40L complex structure (PDB 3QD6). Likewise,
the structural model for the dAb:CD40:CD40L complex
was generated by superposition of oneCD40molecule from
the dAb:CD40 structure onto a CD40 molecule from the
CD40:CD40L complex (PDB 3QD6). The modeling and
surface area calculations were performed using ICM 3.7-2a
(Molsoft, L.L.C. San Diego, CA).Crystallization and X-ray data collection, structure
determination and refinement
Purified complexes were concentrated to 15–18 mg/mL
and subjected to crystallization. For the hCD40/
BMS3h56-5 complex, crystal leads were obtained at
20 °C by mixing 1 μL of complex and 1 μL of well solution.
Two different crystal forms were obtained under the
following conditions: (1) 20% (wt/vol) polyethylene glycol
4000 and 0.2 M potassium formate, 0.1 M citric acid
(pH 3.5), which led to a C2 crystal form and (2) 1.6 M
ammonium dihydrogen phosphate, 20% (vol/vol) Glycerol,Table 1. Data collection and refinement statistics
CD40/Chi220 Fab
Data collection
Space group P42212
Cell dimensions
a, b, c (Å) 201.2, 201.2, 63.8
α,β,γ(°) 90, 90, 90
Resolution (Å) 201.2–3.69 (3.89–3.69)
Rr.i.m. 0.264 (0.525)
I / σI 13.2 (6.8)
Completeness (%) 100 (100.0)
Redundancy 15.9 (16.3)
Refinement
Resolution (Å) 32.64–3.69
No. reflections 14,605
Rwork / Rfree 0.168/0.207
No. of atoms
Protein 4001
Solvent 1 H2O + 2 SO4
2−
B-factors
Protein 42
Solvent 95
R.m.s. deviations
Bond lengths (Å) 0.010
Bond angles (°) 1.4
One crystal was used for each complex.
† Estimated by multiplying the conventional Rmerge value by the factor80 mM Tris (pH 8.5), which led to an I222 crystal form. The
C2 form required two rounds of seeding to obtain
diffraction quality crystals. For the hCD40/Chi220-Fab
complex, crystals were obtained by mixing 1 μL of the
complex and 1 μL of a solution containing 1.6 M ammo-
nium sulfate, 20% glycerol, and 80 mM sodium acetate
(pH 4.6).
X-ray data for the CD40/Chi220 Fab and for the C2
crystal form of the CD40/BMS3h-56-5 complexes were
collected using beamline 08ID-1 [27] at the Canadian Light
Source using a Rayonix MX-225 detector. The X-ray data
for the I222 crystal form of the CD40/BMS3h-56-5 complex
were collected using a Rigaku FR-E rotating anode,
Rigaku MicroMax confocal optics, and a Rigaku Saturn92
detector. All crystals were cooled to 100 K. The data were
processed with XDS [28,29] using autoPROC (Cambridge,
UK, Global Phasing, Ltd.) for the CD40/Chi220 Fab
complex and HKL2000 [30] for the two CD40/BMS3h-
56-5 complex crystal forms. Molecular replacement
was carried out with PHASER [31] using the following
models: Fab: CL:CH1 (PDB 2O5X), VL (3D85), VH
(2ZPK), dAb: VH (2VYR); and CD40: an ensemble created
by ENSEMBLER [32], from 1JMA, 2AW2, 1NCF, 1TNR,
2HEV, 2HEY, and 2UWI and encompassing residues 26–
70 and 95–100 (CD40 numbering) for the N-terminal
domain. The next CD40 domain used residues in 1JMA
corresponding to 71–94 and 101–127. Refinement was
carried out using BUSTER (Cambridge, UK: Global
Phasing Ltd.). Residues that were in contact or buried in
the interaction, which is a less restrictive definition of
interaction than in contact, were determined as previously
described [33,34]. Figures were generated using PyMol
(New York, NY: Schrödinger, Inc.). Data collection and
refinement statistics are summarized in Table 1.CD40/dAb CD40/dAb
C2 I222
199.3, 48.7, 138.8 156.6, 158.8, 200.7
90, 118.2, 90 90, 90, 90
50.0–2.8 (2.9–2.8) 50–3.30 (3.36–3.30)
0.110 (0.512)† 0.139 (0.444)†
14.6 (3.4) 33.7 (12.5)
98.6 (98.0) 99.8 (99.8)
3.2 (3.1) 42.5 (43.6)
50–2.8 29.04–3.30
29,299 33,355
0.229/0.258 0.292/0.324
6144 8340
13 H2O + 3 K
+ 4 SO4
2−
57 66
33 81
0.010 0.010
1.4 1.5
[N/(N − 1)]1/2, where N is the data redundancy.
2865Epitope-Specific Antagonism of CD40At the time of the structure determination (2009–2010)
for the CD40/BMS3h-56-5 complex, the structure of CD40
was not known. Further impeding structures determination
despite having two crystal forms of the CD40/BMS3h-56-5
complex were: (1) an inability to make heavy atom
derivatives by soaking crystals; (2) the absence of
methionines in CD40, although since it was expressed in
mammalian cells, this was an unlikely avenue in any case;
and (3) difficulties using the bacterial expression system
for the dAb with Se-Met. Thus, the structure of the CD40/
Chi220 Fab was originally undertaken to provide a better
CD40 model. Finding the components of the Fab, that is,,
CL:CH1 domain dimer and the VL and VH were relatively
straightforward; however, finding any part of the CD40
required obtaining ENSEMBLER to create an ensemble
model, which then allowed the N-terminal domain to be
located by molecular replacement. Finding the next
domain required using the brute rotation function with a
15° angular range, which was sampled every 1° followed
by the PHASER fast translation function.
Initially, for the CD40/BMS3h-56-5 complex, four copies
of the dAb could be found by molecular replacement in the
I222 crystal form, where it formed columns with vast empty
space in between (Supplementary Fig. 1a), and three
copies of the dAb could be found in the C2 crystal form.
However, none of the available TNF-receptor family
models or domains derived therefrom yielded any
solutions. Upon obtaining ENSEMBLER, the ensemble
of the N-terminal domains described above for the CD40/
Chi220 Fab complex yielded the location in the I222
crystal form of one convincing (TFZ = 8.5; ΔLLG =389)
and three likely (TFZ from 5.7 to 6.0 and ΔLLG from 83 to
116) copies that placed this part of CD40 between the
columns of dAb molecules (Supplementary Fig. 1b).
Molecular replacement using the CD40 model obtained
from the CD40/Chi220 Fab structure found two of these
four domains. Similarly, in the C2 crystal form, the
ensemble of N-terminal domain TNF-receptors was able
to convincingly locate two copies (TFZ 12.1 and 9.0 and
ΔLLG of 165 and 100) and a third likely copy (TFZ 5.8 and
ΔLLG 198).
Molecular replacement did not yield any convincing
solutions for the next CD40 domain in either crystal form,
so non-crystallographic symmetry map averaging with
density modification [35,36] was carried out in the I222
crystal form. This yielded good electron density for one of
the regions between the N-terminal CD40 domains and the
columns of dAbs and various degrees of more challenging
electron density for the other three (Supplementary Fig.
1c). CD40 from the CD40/Chi220 Fab structure and the
TNF-family receptor from 2UWI were superimposed on the
N-terminal domains, and a likely position was found for the
second CD40 domain in the electron density, which was
rigid-body refined by COOT. This position was propagated
to the other three copies. At this point, it was obvious that
CD40 Trp 109 was in the vicinity of CDR3. The model was
refined and the CDRs fitted. From this point forward,
enough of the model had been placed that a “virtuous”
cycle of model-building and refinement had been achieved
(Supplementary Fig. 1d). The CD40 molecules were
transferred to the C2 crystal form, which was completed
first since it was at higher resolution, before using the
C-terminal domains from C2 crystal form to complete the
CD40 structures in the I222 crystal form.Primary cell isolation and culture
Human tonsillar B cells were isolated from tonsils
obtained during routine tonsillectomy by mincing and
gently mashing the tissue, passing the cells through a
screen, and isolating mononuclear cells with density
gradient separation using human Lympholyte separation
media (Cedarlane Labs, Burlington, ON). Mononuclear
cells were collected from the interface, washed, and
rosetted with sheep red blood cells (Colorado Serum
Company; Denver, CO) for 1 h at 4 °C, followed by density
gradient separation to remove T cells. Cells were again
washed and resuspended in RPMI containing 10% FCS
(complete media).
T cell-depleted PBMCs (E-negs) were isolated from
normal human blood donors by density gradient separa-
tion and sheep red blood cells rosetting. E-negs were used
directly for some assays or were used to generate
immature DCs (iDCs) by adhering E-negs to 6-well
polystyrene plates for 1 h at 37 °C/5% CO2, followed by
gentle washing of adherent cells with pre-warmed com-
plete media to remove non-adherent cells. Then, 6 ml of
complete media containing IL-4 (100 ng/ml) and GM-CSF
(100 ng/ml) was added to each well of the 6-well plate, and
the cells were incubated for 6 days at 37 °C/5% CO2,
changing media every other day and replacing it with fresh
media containing the same concentration of cytokines.
iDCs were harvested on day 6, washed thoroughly, and
resuspended in complete media.
Cynomolgus macaque B cells were isolated by mincing
and gently mashing the spleens, passing the cells through
a screen, and isolating mononuclear cells with density
gradient separation. T cells were removed by allowing the
B cells to adhere to nylon wool columns (Dako, Carpen-
teria, CA), gently rinsing off the nonadherent T cells, and
agitating the nylon wool to remove the adherent B cells. B
cells were washed and resuspended in complete media.Primary cell assays
Human or cynomolgus B cell proliferation driven by
soluble hCD40L trimer or CHO-hCD40L. Titrations of
dAb-Fc molecules were made in complete media and
added in triplicate to 96-well round bottom (RB) plates.
Then, 1 × 105 tonsillar human B cells or cynomolgus B
cells were added and stimulated with soluble IZ-hCD40L
(0.6 μg/mL) or with Chinese hamster ovary cells stably
transfected with human CD40L (CHO-hCD40L) plated 1 ×
103 cells/well and irradiated with 10,000 rad in a final
volume of 200 μl. Plates were incubated at 37 °C./5% CO2
for 72 h, labeled for the last 6 h with 0.5 μCi of
3[H]-thymidine per well, harvested, and counted by liquid
scintillation. B cell proliferation was quantitated based on
thymidine incorporation.CHO-hCD40L-driven activation of primary human
monocyte-derived DCs. Titrations of 3h56-258 Fc dAb
was made in complete media and added in triplicate to
96-well RB plates. Then, 8 × 104 iDCs were added per well
and stimulated with irradiated CHO-hCD40L cells (4 × 103
cells/well) in a final volume of 200 μL/well in a 96-well RB
plate. Complete media was included as a media only
control. The plates were incubated at 37 °C/5% CO2 for
24 h. Then, 150 μL of supernatant was removed from
2866 Epitope-Specific Antagonism of CD40each well and tested for cytokines IL-6, IL-12, and TNFα
using commercially available ELISA (R&D Systems) used
according to manufacturer's instructions. For analysis,
triplicate values were averaged and quantitated by
comparison to a standard curve generated with
4-parameter curve fit using SoftMax Pro software (v 5.4,
Molecular Devices, Sunnyvale, CA).
Human and cynomolgus monkey agonism assays. Titra-
tions of CD40 agonistic dAb 3h217-16Fc, CD40 agonis-
tic mAb G28-5, and CD40 antagonist human or monkey-
specific dAbs were diluted in complete media and added
in triplicate to 96-well plates at 100 μL/well, with
complete media used as a media only control. 1 X 106
cells/well of tonsillar human B cells, cynomolgus
monkey B cells, or iDCs (immature human DCs) in
complete media were then added to each well for a final
volume of 200 μL.
For cytokine release assays, human and cyno B cells
were incubated at 37 °C/5% CO2 for approximately 66 h,
150 μL of supernatant was removed from each well, and
supernatants were evaluated for protein concentrations of
human IL-6 and cynomolgus monkey IL-6 using commer-
cially available human IL-6 ELISA (R&D Systems) used
according to manufacturer's instructions. For cell surface
activation markers, iDCs were incubated at 37 °C/5% CO2
for approximately 20 h and then combined into one sample
per triplicate treatment, transferred to 96-well RB polysty-
rene plates, and placed at 4 °C. Cells were washed with
PBS containing 1% BSA, 2.5 μM EDTA (staining buffer),
blocked with 250 μg/mL of human IgG (Jackson Immu-
noResearch), and evaluated for either ICAM-1 or CD86
expression using a FACSCanto II flow cytometer (BD
Biosciences, San Diego, CA) and FlowJo analysis
software (Treestar, Ashland, OR).
Receptor occupancy assays
Healthy donor blood samples were obtained through the
Bristol-Myers Squibb blood donor program. Cynomolgus
monkey blood was obtained from non-study, biologics
naïve animals within BMS. Rhesus macaque and chim-
panzee blood samples were obtained from Bioreclama-
tion. For dAb/CD40 receptor occupancy studies, blood
samples were drawn into vacutainers using ACD-A as the
anti-coagulant. Human and cynomolgus samples were
dAb treated and analyzed within 2 h of blood draw.
Rhesus macaque and chimpanzee blood samples were
shipped overnight on cold packs, and dAb was treated/
analyzed approximately 24 h post-blood draw.
For flow cytometric measurement of PEGylated 3h56-5
and 3h38-2 dAb binding to whole blood B cells, blood
samples were incubated with a titration of each PEGylated
dAb for 1 h at 37 °C and 5% CO2. Then, 100 μl of treated
or untreated blood was transferred to assay tubes, washed
twice with 0.5% FBS/PBS/0.1% sodium azide (FACS
buffer), and placed on ice. To each tube, human IgG
(I 4506; Sigma) was added to block nonspecific Fc
receptor-mediated binding. Blood samples were then
incubated with an anti-PEG monoclonal antibody
(CH2074; Silver Lakes Research). Samples were washed
in FACS buffer, then incubated with a goat anti-mouse IgG,
Fcγ subclass 1 specific secondary antibody (115-115-205;
Jackson Immunoresearch), and allophycocyanin anti-CD20 (2H7; BD Biosciences). For CD40 staining, phyco-
erythrin anti-CD40 was used (5C3; BD). Red blood cells
were lysed and leukocytes were fixed with FACS Lysing
Solution (349202; BD). Cells were acquired on a BD
FACSCanto I (BD Biosciences) and analyzed with
FACSDiva software (BD).Surface Plasmon resonance
Kinetic characterization of representative dAbs from the
3h217, 3h37, 3h38, and 3h56 lineages binding to CD40-Fc
fusion proteins was performed on a Bio-Rad ProteOn
XPR36 SPR instrument. The SPR surfaces were prepared
by immobilizing 8 μg/ml anti-human IgG(Fc) antibody
(Biacore/GE Healthcare) in 10 mM sodium acetate
(pH 4.5) on a Bio-Rad GLC sensor chip using standard
ethyl(dimethylaminopropyl) carbodiimide/NHS chemistry
with ethanolamine blocking. The running buffer for
immobilization and kinetic binding analysis was 10 mM
sodium phosphate, 130 mM sodium chloride, and 0.05%
Tween 20 (pH 7.1). CD40-Fc fusion proteins at concen-
trations of 20 μg/ml were captured in the vertical orienta-
tion on these surfaces via the Fc tail, and reference
surfaces lacking CD40-Fc proteins were used for refer-
ence subtraction. Kinetic experiments were performed by
flowing 405, 135, 45, 15, and 5 nM dAb analytes in the
horizontal orientation over the captured CD40-Fc surfaces
at 25 °C using 240 s association time and 420 s dissoci-
ation time at flow rates of 30 μl/min. The surfaces were
regenerated in both horizontal and vertical orientations
with 30 s pulses of 3 M MgCl2, followed by running buffer
at 60 μl/min. Sensorgram data was double-referenced and
then fitted to a 1:1 Langmuir model using Bio-Rad ProteOn
Manager V.2.1.0.38 software to determine the association
rate constant (ka), the dissociation rate constant (kd), and
the equilibrium dissociation constant (KD).
Competition and CD40L binding and blocking SPR
experiments were performed on a Biacore T100 instru-
ment using a running buffer of 10 mM sodium phosphate,
130 mM sodium chloride, and 0.05% Tween 20 (pH 7.1) at
25 °C. dAb competition experiments utilized a surface
consisting of 800 RU hCD40-Fc immobilized on a CM5
sensor chip using standard amine coupling chemistry.
Competition between dAbs and antibody Fab fragments
for binding to hCD40-Fc was assessed using the “dual
injection” function in the T100 control software by binding
100 nM dAb or Fab, immediately followed by 100 nM
same dAb or Fab or a mixture of 100 nM dAb plus 100 nM
competing dAb or Fab using 180 s association and
dissociation times at 30 μl/min. The surface was success-
fully regenerated between cycles using two 15 s pulses of
10 mM glycine (pH 1.7) at a flow rate of 30 μl/min. CD40L
binding and blocking experiments utilized a surface
consisting of biotinylated IZ-hCD40L captured on a
streptavidin sensor chip (Biacore/GE Healthcare) at a
density of 1100 RU. The binding of 40–5000 nM hCD40
monomer or hCD40-Fc fusion was tested using associa-
tion and dissociation times of 120 s at 30 μl/min. For
receptor blocking experiments, 300 nM hCD40-Fc was
injected in the presence or absence of 0–900 nM dAb,
antibody or antibody Fab fragment, and the binding level
on biotinylated IZ-hCD40L surface was monitored. Bio-
tinylated IZ-hCD40L surfaces were regenerated between
cycles using two 10 s pulses of 3 M MgCl2, at 30 μl/min.
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Identification of dAbs targeting hCD40
dAbs were selected for binding to recombinant, biotinyl-
ated, and monomeric hCD40 fragment by phage display
[21] from large (N1010 colony-forming units) synthetic VH
and Vκ dAb libraries [22]. These libraries are based on fully
human germline scaffolds with targeted diversification of a
subset of hypervariable loop residues known to be
involved in antigen interaction. Nine different lineages of
anti-hCD40 dAbs were identified from initial selections,
four examples of which (3h37, 3h38, 3h56, and 3h217) are
shown in Table 2. The potencies (EC50) of the parent dAb
molecules in inhibiting CD40L-driven proliferation of
primary human B cells ranged from ~700 nM to
N7000 nM. Each of the parent dAb molecules was
subjected to a first round of maturation involving diversi-
fication of the binding loops using random mutagenesis.
Phage selection of these libraries led to isolation of dAbs
with improved dissociation rates and 20- to 680-fold
increases in potency in primary cell assays (Table 2).
Select affinity matured clones were subjected to a second
round of maturation via targeted mutations of complemen-
tarity-determining region (CDR) residues using
oligonucleotide-directed mutagenesis. This resulted in
the identification of clones with further improved dissoci-
ation rates and potencies. For example, in the primary
human B cell assay, the potency of the parent 3h56 dAb
was ~700 nM; after the first round of maturation, theTable 2. Potency of parent CD40 dAbs and their affinity matu
dAb Clone Human B cell Proliferation
EC50 (nM)
3h37 3400.0 ± 2900.0 nd
3h37-1 25.0 ± 10.0
3h37-2 5.0 ± 2.0 32.0
3h37-202 0.6 ± 0.2 14.0
3h37-205 2.0 ± 1.0 32.0
3h38 2800.0 ± 400.0 nd
3h38-1 142.0 ± 86.0
3h38-2 10.0 ± 6.0 288.
3h38-211 2.0 ± 1.0 30.2
3h38-215 1.0 ± 0.0 11.3
3h38-217 0.8 ± 0.2 6.0 ±
3h56 713.0 ± 133.0
3h56-1 7.0 ± 5.0
3h56-2 3.0 ± 1.0 71.0
3h56-5 6.0 ± 4.0 117.
3h56-6 4.0 ± 3.0 142.
3h56-7 8.0 ± 6.0 211.
3h56-201 0.12 ± 0.04 1.1 ±
3h56-206 0.1 ± 0.01 0.6 ±
3h217 3200 ± 2030
3h217-1 45 ± 26
3h217-5 13 ± 5
3h217-6 11 ± 3
3h217-14 26 ± 10
3h217-15 47 ± 21
3h217-16 5 ± 2
3h217-23 16 ± 6
3h217-30 80 ± 9
a Experimental errors represent the standard deviation of at least th3h56-2 clone was identified with a potency of ~3 nM, and
after further maturation of 3h56-2, the 3h56-206 clone was
identified with a potency of 0.1 nM (Table 2). The most
potent affinity-matured clones were from the 3h56, 3h37,
and 3h38 lineages, which had 3000–7000-fold increase in
potency in the B cell assay over the parent molecules.
Similar trends were also noted for affinity-matured dAb
molecules when tested in the primary human DC activation
assay measuring inhibition of CD40-dependent production
of IL-6, IL-12, and TNF (Table 2). Several clones either did
not gain in potency or exhibited a loss of potency and are
not listed in Table 2.
Binding of anti-CD40 dAbs to human and primate B cells
The hCD40 molecule shares a high degree of sequence
similarity with the NHP CD40 sequences (N95% identity)
but is vastly different from the murine CD40 sequence
(58% identity). Indeed, previous mAbs targeting hCD40
have been studied in NHPs, particularly rhesus, cynomol-
gus monkeys, and marmosets [37–42]. To ensure that
NHPs could be used for in vivo studies, we measured the
binding of anti-hCD40 dAb clones from the lead 3h56 and
3h38 lineages to peripheral B cells in human and primate
blood using flow cytometry. When human blood samples
were incubated with 3h56-5 and 3h38-2, dose-dependent
binding to CD20+ B cells was observed. In contrast,
3h56-5 and 3h38-2 were unable to bind CD20+ B cells in
cynomolgus, chimp, or rhesus blood (Fig. 1a and b). CD40
expression was confirmed using an anti-CD40 antibodyred clones in primary human cell assaysa
Human Primary Dendritic Cell Activation EC50 (nM)
IL-6 IL-12 TNF
nd nd
± 19.0 58.0 ± 43.0 60.0 ± 37.0
± 3.0 14.0 ± 11.0 25.0 ± 6.0
± 15.0 46.0 ± 34.0 57.0 ± 22.0
nd nd
0 ± 307 683.0 ± 686.0 649.0 ± 499.0
± 13.0 18.0 ± 17.0 87.0 ± 59.0
± 6.6 7.0 ± 4.0 25.0 ± 14.0
4.0 1.8 ± 0.4 9.0 ± 4.0
± 62.0 221.0 ± 159.0 143.0 ± 101.0
0 ± 50.0 240.0 ± 115.0 245.0 ± 62.0
0 ± 89.0 285.0 ± 139.0 270.0 ± 86.0
0 ± 132.0 347.0 ± 185.0 447.0 ± 239.0
0.4 0.9 ± 0.6 1.9 ± 1.0
0.3 0.6 ± 0.4 1.1 ± 0.7
ree independent measurements.
2868 Epitope-Specific Antagonism of CD40that cross-reacts with both human and primate CD40
(clone 5C3), indicating that the lack of binding of anti-CD40
dAbs to primate B cells was not due to lack of measurable
CD40 levels (Fig. 1c). Furthermore, when tested with
cynomolgus primary B cells, these dAbs did not exhibit any
functional activity in terms of inhibiting B cell proliferation
(data not shown). The lack of cross-reactivity suggested
that the lead dAb molecules target a unique binding site
specific to hCD40.
Molecular modeling predicts dAb binding sites
To better characterize the dAb binding sites, we
generated a structural model of hCD40 based onFig. 1. Binding of anti-CD40 dAbs to B cells in human and
PEG) and 3h38-2-P40B (tagged with a 40KDa branched PEG
binding was detected by flow cytometry using a mouse anti-PEG
IgG secondary antibody for detection. Data represent results
confirmed in subsequent studies (n = 2). All graphs represent m
of 3h56-5-P40L to cynomolgus, rhesus, chimp, and human
cynomolgus, rhesus, chimp, and human CD20+ peripheral B ce
with phycoerythrin-labeled anti-CD40 clone 5C3, which bindshomology with other TNFR family members (Fig. 2). The
model was further refined using the data from a detailed
mutational analysis, which identified critical residues from
CD40 that interacted with the CD40L protein [43,44]. In
addition, we mapped the polymorphic residues between
human and NHP CD40 on the structural model. The
sequences of cynomolgus and rhesus CD40 were known,
and the sequence of chimpanzee CD40, which had not
previously been reported, was obtained by sequencing the
individual CD40 exons from chimpanzee's genomic DNA,
and the coding sequence was compiled and aligned using
the human gene as a guiding template. Surprisingly, the
chimpanzee CD40 sequence was found to differ from
hCD40 only at position 109 (R109 in chimpanzee, W109 inprimate blood. 3h56-5-P40L (tagged with a 40 kDa linear
) were incubated with blood samples for 1 h at 37 °C. dAb
primary antibody and a phycoerythrin-labeled anti-mouse
from a single primate or human blood sample and were
edian fluorescence intensity on CD20+ B cells. (a)Binding
CD20+ peripheral B cells. (b)Binding of 3h38-2-P40B to
lls. (c) CD40 levels on human and primate B cells detected
to both human and primate CD40.
Fig. 2. Sequence and structural model of human and NHP CD40. (a) Sequence alignment of hCD40 (accession
number NP_001241.1) with NHP species: chimp (sequence determined in house, identical to XP_009435602.1),
cynomolgus (accession number XP_005569275.1), and rhesus (accession number EHH19629.1). The sequence is
colored by consensus strength (similarity) with identical residues colored green. Critical residues often found as motif
anchors (C, W, Y, F, H, P) are colored darker green. The colored bar above the alignment delineates functional regions of
CD40: yellow = signal peptide, red = extracellular domain corresponding to the region for which homology modeling was
performed, magenta = extracellular domain with no structural template, cyan = Type 1 transmembrane domain, and
orange = cytoplasmic domain. (b) Structure-based alignment for six TNF receptor superfamily members: (PDB codes)
1JMA = Herpes simplex virus glycoprotein D bound to the human receptor HveA; 2AW2 = BTLA–HVEM complex;
2UWI = CrmE, a virus-encoded tumor necrosis factor receptor; 2HEV = OX40–OX40L complex; 1NCF = tumor necrosis
factor receptor; and 1TNR = TNF beta complex. (c) hCD40 structural homology model. Residues colored in red have been
shown to be involved in CD40L binding [43,44], while those colored in cyan are variant residues among the extracellular
domain of primate CD40 within the modeled region.
2869Epitope-Specific Antagonism of CD40human), which was also a polymorphic residue in
cynomolgus and rhesus (L109), strongly implicating this
residue as being crucial in conferring the species-specific
dAb binding. Moreover, the W109 residue along with the
adjacent L121 residue and the distal H76 residue located
within the N-terminal region of hCD40 were the only three
polymorphic positions identified by the structural model toreside on the same face of CD40 as the CD40L binding
site. Consequently, these three residues were targeted for
site-directed mutagenesis and epitope mapping SPR
studies to identify the dAb-binding sites. An X-ray crystal
structure of the hCD40:hCD40L complex has since been
determined and confirmed the involvement of H76, W109,
and L121 residues in binding to CD40L [45].
2870 Epitope-Specific Antagonism of CD40Identification of dAb binding sites
Representative dAbs from the four most potent lineages
(3h37, 3h38, 3h56, and 3h217) were next tested for
binding to wild type and mutant CD40 proteins using
surface plasmon resonance (SPR) and were compared to
the binding of the monovalent Fab fragments generated
from the agonist G28-5 antibody [46] and the Chi220
antibody, which has been reported to possess weak
agonist activity [26]. The G28-5 Fab fragment and the
3h217 lineage dAbs bound equally well to all of the CD40
proteins tested, suggesting that the binding sites for these
molecules do not depend on residues 76, 109, or 121
(Table 3). The Chi220 Fab fragment bound with compa-
rable affinity to all CD40 proteins containing H76 but
25-fold weaker to all CD40 containing the H76➔R
mutation, suggesting that the Chi220 binding site includes
H76 of hCD40. In contrast, dAbs from the 3h37, 3h38, and
3h56 lineages bound equally well to hCD40 and
hCD40-H76R but not to any of the CD40 proteins
containing NHP residues at positions 109 or 121,
implicating these residues in the binding site for each
dAb from these hCD40-specific lineages (Table 3). The
importance of W109 and L121 was also confirmed using
mutant cyCD40 proteins engineered to contain
hCD40-specific residues W109 and L121 (Supplementary
Fig. 2).
To complement the mutagenesis data, we performed
competition SPR binding studies to map the dAb and
antibody binding sites relative to each other. For these
studies, representative dAbs from each lineage were
injected over CD40-Fc surfaces in the absence or
presence of competitor dAb or antibody Fab fragment,
and the binding was compared in the presence or absence
of competition. These experiments revealed two sets of
competing molecules: dAbs from the hCD40-specific
3h37, 3h38, and 3h56 lineages were all competitive withTable 3. Dissociation constant (KD, in nM) values determined
proteins using SPRa,b
Lineage / parent
molecule dAb / Fab
wt-
hCD40c
hCD40-
(H76R)
hCD40-
(W109L)
3h37 3h37-2 2.0, 2.0 2.6 X
3h37-11 1.9, 2.3 2.4 X
3h38 3h38-2 5.1, 8.0 7.2 X
3h38-211 3.3, 6.1 4.0 X
3h38-215 2.1, 6.0 3.0 X
3h38-217 2.3, 2.4 3.4 X
3h56 3h56-1 3.0, 5.4 4.2 29
3h56-2 3.8, 3.2 6.1 44
3h56-5 5.3, 4.7 7.2 65
3h56-202 2.3, 1.3 3.3 155
3h56-206 0.6, 1.4 0.96 55
3h217 3h217-5 0.47, 0.48 0.94 0.99
3h217-16 0.22, 0.26 0.35 0.41
3h217-23 0.78, 1.5 1.6 2.0
Chi220 Ch220-Fab 0.91 25 1.0
G28-5 G28-5-Fab 0.81 0.86 0.91
a X indicates very weak (estimated Kd N 1000 nM) or no detectable
b NT = not tested.
c Values for dAbs binding to wt-hCD40 were recorded in duplicate.each other for CD40 binding but did not compete with
3h217, Chi220-Fab, or G28-5-Fab, while 3h217, Chi220-
Fab, and G28-5-Fab were competitive with each other but
did not compete with the hCD40-specific dAbs (Fig. 3a and
b). Collectively, the CD40 mutant and competition SPR
data suggest that each of the hCD40-specific dAbs binds
to a unique epitope including residues W109 and L121 of
hCD40, while 3h217, Chi220, and G28-5 bind to a distal
region on the N-terminal domain of hCD40, with the H76
residue being part of the binding epitope of Chi220 but not
G28-5 or the 3h217 dAbs.
dAbs are competitive with CD40L
We next tested whether dAb binding to the unique site
on hCD40 would block the engagement of the receptor
with CD40L by performing competition studies to assess
the binding of hCD40-Fc to hCD40L surfaces in the
absence or presence of dAbs, mAbs, or Fab fragments.
Here, hCD40-Fc binding could be blocked in a
concentration-dependent manner in the presence of
dAbs from all lead lineages including 3h56, 3h38, 3h37,
and 3h217 or in the presence of Chi220 antibody or
Chi220-Fab fragment (Fig. 3c and e). In contrast, the
G28-5 antibody and Fab fragment each influenced the
kinetics of CD40 binding to CD40L trimer but did not
completely block this interaction (Fig. 3d and e). In
particular, the increased binding response for hCD40-Fc
in the presence of the bivalent G28-5 antibody is
consistent with antibody-dependent cross-linking of
CD40-Fc on the CD40L trimer surface (Fig. 3d).
Structure of CD40 complexes
To further characterize the binding interactions of the
dAbs and antibodies, the structure of hCD40 was
determined in complex with the human-specific dAbfor dAbs and Fab fragments binding to CD40-Fc fusion
hCD40-(W109R) /
chimp-CD40
hCD40-
(W109 L,
L121P)
hCD40- (H76R,
W109L, L121P) cyCD40
X X X X
X X X X
X X X X
X X X X
X X X X
X X X X
X X X X
X X X X
X X X X
X X X X
X X X X
0.72 0.93 0.99 0.86
0.27 0.35 0.47 0.43
1.2 1.6 2.2 1.9
NT 1 26 26
NT 0.92 0.97 0.98
binding.
Fig. 3. hCD40-specific dAbs bind to a unique site and are noncompetitive with human/NHP cross-reactive molecules.
(a) SPR sensorgram data show that the binding of 3h56-5 to hCD40-Fc surface blocks the binding of hCD40-specific dAbs
3h37-2 and 3h38-2, but not hCD40/cyCD40 cross-reactive molecules 3h217-5, Chi220-Fab, or G28-5-Fab. (b) Summary
of SPR competition experiments performed as in panel (a) for different combinations of dAb or Fab pairs, where “x”
indicates no competition and “✓” indicates that the molecules compete for hCD40 binding. (c) 3h56-5 blocks hCD40-Fc
binding to IZ-hCD40L surface in a concentration-dependent manner. (d) G28-5 mAb does not block hCD40-Fc from
binding to IZ-hCD40L surfaces. (e) SPR binding responses for hCD40-Fc binding to CD40L trimer surface in the absence
or presence of various dAbs, antibodies, or Fab fragments. The ratios in panels (c–e) correspond to that for monovalent
dAb or Fab fragments or for the monovalent binding unit of the bivalent hCD40-Fc dimer or bivalent Chi220 or G28-5
antibodies.
2871Epitope-Specific Antagonism of CD403h56-5 and separately in complex with the Chi220-Fab
fragment. In complex with the dAb, a longer region of the
hCD40 structure could be interpreted, ranging from
residues 24 or 26 to 188 or 190 for the three unique
molecules in the C2 crystal form asymmetric unit (Fig. 4a).In contrast, only 98 residues (residues 24–121) of hCD40
could be interpreted in the hCD40:Chi220-Fab structure,
with the remaining residues being disordered. The
complex of CD40 with the dAb represents a sequence
length equal to the longest stretches of TNF superfamily
Fig. 4. Structures of the hCD40/Chi220-Fab and hCD40/3h-56-5 dAb complexes. (a) Cartoon diagram of hCD40 in the
hCD40/3h-56-5 dAb complex showing residues 24–190 encompassing domains 1–4. (b) Superposition of hCD40/
Chi220-Fab complex on the hCD40/3h-56-5 dAb complex showing the spatially distinct epitopes for 3h56-5 and
Chi220-Fab. The positions of hCD40 H76, W109, and L121 are shown with carbon (cyan), nitrogen (blue), and oxygen
(red). (c) Interaction between 3h-56-5 dAb and hCD40, with the dAb represented as a gray surface with in-contact atoms in
orange and buried atoms in yellow. hCD40 is represented as a cartoon with non-interacting residues in magenta and
buried residues in slate and their side chains with carbon (cyan), nitrogen (blue), and oxygen (red) atoms. (d) Interaction
between hCD40 and 3h-56-5 dAb with hCD40 shown as a gray surface with in-contact atoms in orange and buried atoms
in yellow. The dAb is represented as a cartoon with β-strands in red, CDR residues in slate, other loops in magenta, and
interacting residues with carbon (cyan), nitrogen (blue), and oxygen (red) atoms. (e) Interactions between hCD40 residues
W109, L121, and H122 in the hCD40 chain A/3h-56-5 dAb chain B complex. (f) Interactions between hCD40 residues
W109, L121, and H122 in the CD40 chain D/3h-56-5 dAb chain E complex. Note the different positions of 3h-56-5 dAb
W103 in the two complexes (panels e and f). In panels (e) and (f), the 3h-56-5 dAb is shown with gray carbon atoms and the
hCD40 is shown with green carbon atoms, nitrogen and oxygen atoms are shown in blue and red, respectively.
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dA
3 3 3 3 3 3 3receptors that have been previously observed (e.g.,
RANK, PDB 3ME2, and 3ME4). In particular, it is longer
than the region of hCD40 (residues 21 or 26 to 145) that is
observed in the complex of hCD40 with hCD40L, PDB
3QD6 [45]. The 40+ additional residues that are ordered in
the CD40/dAb complex continue with the TNF receptor
superfamily motif of domains known as “Cysteine-rich
domains” [47], which have limited secondary structure and
are held together by disulfide bonds.
Consistent with the SPR competition experiments, the
Chi220-Fab and 3h56-5 bind to entirely separate epitopes,
as shown in Fig. 4b. The Chi220-Fab interacts with the
N-terminal cysteine-rich domain of hCD40 known as
domain 1 [48], with an epitope consisting of residues K46,
L47, V48, S49, D50, T52, L60, G63, E64, E66, R73, T75,
H76, and C77, and a molecular surface area of 595 Å. The
side chain of H76, which was also identified bymutagenesis
as a Chi220 binding residue (see above), contributes to the
interaction and is on the edge of the epitope.
In contrast to Chi220-Fab, the 3h56-5 dAb interacts with a
region of hCD40 that is further toward the C-terminal region of
the extracellular domain, with an epitope including residues
W109, V120, L121, H122, S124, S156, A157, F158, E159,
and H162 (Fig. 4c). Interestingly, despite the smaller size of
the dAb, the buriedmolecular surface area of 705 Å (average
of 3 independent complexes in the C2 crystal form) is larger
than that of the Chi220-Fab. The critical W109 and L121
residues are adjacent to each other in the tertiary structure of
hCD40, where they form a distinct hydrophobic handle that is
solvent exposed at the edge of a bend near the junction
between domains 2 and 3. The paratope on 3h56-5 includes
residues (Kabat numbering): E33, W35, L45, A50, I51, N52,
R56, T57, Y58, L95, F97, F99, W103, (Fig. 4d).
A closer analysis of the hCD40/dAb interactions shows
that L121 and H122 of CD40 bind in a trough that is open at
one end on the dAb surface, with the floor consisting of
framework residues V37 and A93 and the walls consisting
of framework residues L45 and R47, as well as CDR3
residues F97, T98, and F99, and one end is closed by the
side chain of W35 (CDR1) (Fig. 4d). The side chain of
hCD40 residue L121 interacts with the side chains of
3h56-5 residues V37, L45, R47, and F97, and forms
additional interactions with W103 in two of the three
complexes in the asymmetric unit. W109 of hCD40 binds
to the dAb just beyond the edge of the trough, with the
W109 side chain interacting with the dAb through residues
L45, T98, F99, and in particular with W103. hCD40 residue
W109 and 3h56-5 residueW103 demonstrate two different
modes of interaction in the CD40 chain A, dAb chain B
complex, the edge of W109 points toward the face of
W103, whereas in the other two complexes in the
asymmetric unit, the two tryptophan side chains are
parallel but offset and thus not fully stacked (Fig. 4e and
f). This suggests that at least two similar, but conforma-
tionally distinct, modes of interaction occur between CD40
and the dAb. Omit map density for regions of interest is
shown in Supplementary Fig. 3.Generation of an epitope-specific anti-cynomolgus monkey
CD40 surrogate dAb
To better understand the biological effects of dAb
binding to the unique CD40 epitope and to enable in vivo
studies in cynomolgus monkeys, we generated surrogate
2874 Epitope-Specific Antagonism of CD40dAb molecules that were specific for the L109/P121
epitope of cyCD40. Initial selections were performed
using recombinant cyCD40 protein and the same phage
display technology as the human dAb selections, yielding
dozens of low affinity clones (EC50 0.5–3.0 μM). These
molecules were first screened to identify those molecules
that were active in cynomolgus B cell assay but not human
B cell assay. The cynomolgus-specific clones were
subsequently tested by SPR using the panel of mutant
CD40-Fc proteins described above to identify those clones
that bound specifically to the L109/P121 epitope of
cyCD40 but not to the W109/L121 epitope of hCD40.
This two-stage screening approach identified three clones
(3c68, 3c75, and 3c85) that appeared to bind to the L109,
P121 epitope of cyCD40 (Table 4). These dAbs were
taken into affinity maturation, from which the 3c85 lineage
yielded multiple high potency/affinity variants that retained
specific binding to the L109/P121 epitope of cyCD40, with
no cross-reactivity to hCD40 (Table 4).
dAbs that bind to the species-specific
residue109/121 epitope are pure antagonists
Previous studies have shown that the agonistic properties
of G28-5 are related to the valency of the molecule, since an
intact dimeric mAb or bivalent F(ab)2 molecule exhibited
potent agonism, whereas the monovalent G28-5-Fab
fragment lacked activity [49]. Therefore, to test whether
the dAbs demonstrated similar valency-dependent activity,
we formatted them as Fc-fusion proteins to generate
bivalent dAb-Fc molecules and compared their activity to
G28-5 in various primary human cell assays including the
activation of primary DCs asmeasured by increase in levels
of CD86 and ICAM-1 and the activation of primary human B
cells—either via direct proliferation or IL-4-dependent
production of IL-6. Consistent with earlier studies, we
found the bivalent G28-5 or G28-5-Fab2 molecules to be
potent agonists in these assays, whereas the monovalent
G28-5-Fab was not (Fig. 5a–d). dAb-Fc molecules
generated from the 3h217 lineage, which have overlap-
ping binding site to G28-5 within the N-terminal region of
hCD40 and are human/cyno cross-reactive, were also
potent agonists in both human and cyno B cell assays
(Fig. 5c–e). In striking contrast, the hCD40-specific
dAb-Fc molecules from the 3h37, 3h38, and 3h56
lineages exhibited no agonism in any primary human
cell assays (Fig. 5a–d). Similar results were obtained
when the cyCD40-specific surrogate 3c85 dAbs were
formatted as Fc proteins and tested in primary cynomol-
gus cell assays, where no increase in IL-6 was observed,
whereas the human/cynomolgus cross-reactive
3h217-16-Fc molecule potently induced IL-6 (Fig. 5e).Discussion
Early efforts targeting the CD40 protein were primarily
aimed at generating antagonist mAbs for treatment of
autoimmunity. This work identified mAbs such as Chi220,
4D11, 5D12, and 38A that were effective in prolonging
graft allograft survival in primates; however, these mAbs all
still retain partial agonist activity [26,46,50]. This led to
extensive research on characterizing the relationship
between antibody binding affinity, epitope, and CD40Lblocking with activity. For example, using a panel of 12
anti-murine CD40 mAbs, Barr and Heath showed a
correlation between the ability to block CD40L binding
and the ability to induce strong activating signals to B cells,
but no correlation between B cell activation and antibody
binding affinity or isotype [51]. Similar results were also
reported for a panel of anti-hCD40 mAbs [46]. However,
the functional requirement for ligand competition is not
absolute, since other potent agonist mAbs have been
identified that do not compete with CD40L [52], as well as
those that synergize with CD40L or with a second
noncompetitive antibody to stimulate B cells [53–55].
Recent studies in mice have also shown that
FcR-dependent cross-linking can further enhance signal-
ing [56,57], although this does not appear to be an
absolute requirement and may also be epitope dependent
[58]. Moreover, Glennie and co-workers showed that
activity can be enhanced using antibodies with different
hinge structures [59]. Collectively, these studies suggest
that the link between ligand blocking, activity, and structure
is complex, and that targeting unique epitopes may have
different biological outcomes.
Interestingly, the vast majority of anti-CD40 mAbs in the
literature have been reported to bind within the N-terminal
region of CD40, with most mAbs being mapped to domain
1 [46,52,54]. Similar results have also been obtained
using phage display technology to select for single
chain antibody fragments (scFv), where the distribution
of molecules that were identified was heavily skewed
toward the N-terminal region [60]. Our X-ray crystal
structure and epitope mapping data demonstrate that
Chi220, G28-5, and the 3h217 linage dAbs also map to
this N-terminal domain, suggesting that this region is highly
immunoreactive. Even so, a single dominant epitope does
not appear in this region, as suggested by the noncompet-
itive binding observed for many of these molecules,
including Chi220, G28-5, and the 3h217 lineage dAbs,
which all compete with each other, whereas only Chi220
and 3h217 directly block CD40L, and only Chi220 has an
epitope that depends on H76.
To potentially expand the epitope space in targeting
CD40, we used a novel domain antibody technology to
identify therapeutic candidates. Despite the smaller size of
the dAb molecules, the selection and affinity maturation
strategy was able to identify dozens of clones with high
affinity and potency comparable to that commonly ob-
served for therapeutic mAbs. Characterization of the most
potent dAbs using mutagenesis, epitope mapping, and
X-ray crystallography identified the dAb binding site as a
novel epitope within the C-terminal region of the CD40
extracellular domain, which involves the hCD40-specific
amino acids W109/L121 on domain 3. This hydrophobic
handle on hCD40 is grasped primarily by 3h56-5 residues
from CDR1 and CDR3 including E33, W35, L95, P96, F97,
T98, and F99. However, several residues from the regions
of the dAbs IgG framework residues are also involved in
binding, including V37, L45, and W103, and access to
these residues would be blocked in a conventional Fab by
the VL domain. Therefore, the dAb as a single-domain
binding protein has expanded the binding footprint beyond
the CDRs while maintaining full antibody-like affinity and
potency. This is similar to the examples of other
single-variable domain proteins [61] and single-domain
proteins derived from 10th type III domain of human
fibronectin that also use residues beyond those that were
Fig. 5. Cell surface receptor expression and cytokine release in response to human and cyno anti-CD40 dAb-Fc
molecules. Human monocyte-derived DCs were exposed to increasing concentrations of anti-CD40 antibody G28-5 or
dAb-Fc, with ICAM (panel a) or CD86 (panel b) expression measured on the cell surface at 24 h post-treatment. Similarly,
human tonsillar B cells (panels c and d, each representing a different donor) or cynomolgus splenic B cells (e) were
exposed to increasing concentrations of G28-5 antibody, G28-5-(Fab)2, or G28-5-Fab fragments or dAb-Fc in the
presence of IL-4, with IL-6 production measured 72 h post-treatment. Error bars represent the standard deviation of three
independent titrations. Similar results were obtained for dAbs formatted with modified IgG4 “Fc” and modified IgG1 “Fc2”
Fc domains.
2875Epitope-Specific Antagonism of CD40diversified to interact with a target and that also achieve
affinities in the sub-nanomolar range [62]. Interestingly, the
key framework residues and some of the CDR residuesinvolved in hCD40 contacts are also present in the other
hCD40-specific 3h37 and 3h38 dAb lineages, which were
derived from variable heavy chain dAb libraries but not in
2876 Epitope-Specific Antagonism of CD40the 3h217 lineage that was derived from a kappa variable
domain scaffold, suggesting that the 3h37 and 3h38 dAbs
may interact with hCD40 in a similar manner to 3h56-5.
Considering that the primary interactions between CD40
and CD40L involve domains 1 and 2 of CD40, but the
hCD40-specific 3h37, 3h38, and 3h56 dAb lineages target
domain 3, the potent blocking of the CD40/CD40L
interaction by these dAbs is somewhat surprising. To
better rationalize these findings, we generated structural
models of the 3h56–5/hCD40 and Chi220-Fab/hCD40Fig. 6. Structural model of CD40 complexes. (a) Structure o
chain = gray, CD40 = magenta) superimposed on that of CD40
a distinct steric clash between Chi220-Fab and CD40L. (b) St
CD40 = magenta) superimposed on that of PDB:3QD6, show
terminus and CDR3 of the dAb.complexes superimposed on the hCD40/hCD40L struc-
ture (PDB 3QD6). The model clearly showed extensive
overlap in the binding epitopes and the three-dimensional
space occupied by Chi220-Fab and CD40L, explaining
why Chi220 is a strong CD40L blocker (Fig. 6a). The 3h56-5
dAb, on the other hand, occupies a space near the base of
where CD40L binds, with the model identifying only a small
clash area consisting of dAb residues from two regions (Fig.
6b). The major clash occurs in the CDR3 of the dAb
composed of residues T98, F99, and D101 and a minorf Chi220-Fab:CD40 (Chi220-Fab heavy chain = blue, light
:CD40L complex (PDB:3QD6) (CD40L = green), showing
ructural model of 3h56-5 dAb:CD40 complex (dAb = pink,
ing a small steric clash between CD40L and both the N
2877Epitope-Specific Antagonism of CD40clash with the N terminus of the dAb involving residues E1
and V2. The residues from CD40L that clash with dAb
residues are S214 (with E1 and V2 of the dAb), K216 (with
D101 and T98 of the dAb), P217 (with D101 and F99 of the
dAb), and C218 (with D101 of the dAb). The steric clash
between the molecules involves approximately 250 Å2 of
contact area, which is about 1/3 of the buried surface area
seen typically for antibody–antigen complexes. However,
this clash could provide sufficient energy to block CD40L
from engaging CD40, especially considering that the
monovalent CD40/CD40L interaction is quite weak (Sup-
plementary Fig. 4 and Ref. [63]), whereas 3h56-5 binds with
very high affinity. It is also tempting to speculate that the
dAb binding to domain 3 and potentially domain 4, which are
near the membrane-spanning region, might also impact
signaling by either altering the CD40 structure near the
membrane-spanning region and/or potentially impact
CD40L-mediated clustering of CD40 on the cell surface.
Unlike most previously reported antibodies that demon-
strate varying levels of agonist activity, the 3h37, 3h38,
and 3h56 dAbs were found to remain pure antagonists
even when formatted as pharmacokinetically enhanced
bivalent Fc-fusion proteins. This suggests that targeting
the novel, human-specific W109/L121 epitope may lead to
effective immune modulation through CD40/CD40L block-
ade while avoiding the undesirable toxicities that have
plagued earlier CD40 mAbs in the clinic. Due to the high
sequence homology between human and NHP CD40,
previous clinical candidates such as G28-5 and others
have widely been found to be cross-reactive with NHP
species used in nonclinical safety evaluation tox studies,
particularly in cynomolgus monkeys. Even Chi220, which
has significantly reduced monovalent affinity for cyCD40
(Table 3), retains sufficiently high avidity in a bivalent
format that is suitable for NHP studies (Supplementary
Fig. 5). However, the exquisite specificity of our lead dAbs
for the antagonistic W109/L121 epitope of human CD40
precludes the use of these molecules in NHP tox studies
and requires the co-development of a surrogate dAb for
nonclinical safety evaluation. Here, the 3c85 lineage dAbs
were developed as a suitable surrogate due to the same
epitope (L109/P121) of cyCD40 and comparable affinity
and activity, including functional antagonism even in the
bivalent dAb-Fc format. Collectively, these data support
the progression of a 3h56 lineage dAb-Fc clinical
candidate targeting the unique antagonist W109/L121
hCD40-specific epitope that has the potential for reduced
toxicity and improved efficacy in the treatment of autoim-
mune diseases.
Accession codes
Protein Data Bank: coordinates and structure ampli-
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crystal form).
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